Key takeaways of the evidence-based consensus statement
Accelerated partial breast irradiation (APBI) allows appropriately selected patients with early-stage breast cancer to complete adjuvant radiation in one week or less following breast conserving surgery. To date, multiple randomized trials have demonstrated no difference in rates of recurrence or survival with APBI delivered using brachytherapy or external beam radiation techniques.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this video, Cleveland Clinic radiation oncologist Chirag Shah, MD, discusses the American Society of Radiation Oncology’s newly released updated guidelines for the off-protocol use of APBI. Most significantly, the guidelines lower the age cut-off from age 60 and older to age 50 and older, as well as include patients with ductal carcinoma in citu (low/intermediate grade, < 2.5 cm, negative surgical margins).
Dr. Shah also explains that suitable candidates for APBI include those 50 years or older with tumors < 3.0 cm, with negative margins, and that are estrogen receptor positive. With respect to intraoperative radiation (IORT), the new guidelines recommend counseling that IORT is associated with higher rates of local recurrence and that electron IORT be limited to only suitable APBI patients, while low-energy X-ray IORT should be limited to prospective registries or clinical trials.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients